Redeye maintains the valuation of BioArctic at SEK 150 per share after the positive topline results from Eli Lilly's phase 2 study with donanemab. This study confirms the validity of the amyloid-beta hypothesis for the treatment of Alzheimer's disease, in our view. For 2021 we expect publications of results and presentations at Alzheimer's conferences to provide further detail and a tailwind for the BioArctic stock price.